Navigation Links
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS)

s a disease modifying treatment for multiple sclerosis (MS). Active Biotech developed laquinimod and licensed it to Teva Pharmaceutical Industries, Ltd. in June 2004. A previous 24-week Phase IIa trial conducted by Active Biotech demonstrated that oral 0.3 mg laquinimod given daily was well tolerated and reduced the formation of active lesions in RRMS. To date, 460 MS patients have received laquinimod in various clinical trials.

About MS

Multiple Sclerosis (MS) is the leading cause of neurological disability in young adults. It is estimated that 400,000 people in the United States are affected by this disease, and that over one million people are affected worldwide. MS is a progressive, demyelinating disease of the central nervous system affecting the brain, spinal cord and optic nerves.

Patients with MS may experience physical symptoms and/or cognitive impairments, including weakness, fatigue, ataxia, physical dysfunction, bladder and bowel problems, sensory effects, and visual impairment. MS also has a significant impact on the sufferers' social functioning and overall quality of life.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

About Active Biotech

Active Biotech AB (ACTI.ST) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:8/20/2014)... and PHOENIX , Aug. ... to bring cutting-edge next-generation sequencing and proteomic diagnostics ... today announced a collaboration with TESARO, Inc.  Paradigm ... patient tissue samples from clinical trials to better ... to TESARO,s TSR-011.  This may lead to more successful ...
(Date:8/20/2014)... ApolloDx™ today announced it will unveil and ... event at the company,s office in Salt ... The event, which will start at 10:00 a.m., will ... .    "We believe our mobile diagnostic ... , Co-Founder and Managing Partner of ApolloDx. In addition ...
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
Breaking Medicine Technology:Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2
... COGENT-1 Study of CGT-2168 Expands to Europe; Focus ... Gastrointestinal Side Effects of Antiplatelet Therapy, ... Pharmaceuticals,Inc. today announced that the first patient has ... 3 study of its novel combination medicine,CGT-2168. The ...
... Motion Technologies,announced the completion of the first surgical ... System (TM) (TSMS(TM)), the first total,joint replacement system ... and posterior dynamic stabilization device (PDS). The,successful procedure ... Numune,Education and Training Hospital by Dr. Erkan Kaptanoglu, ...
Cached Medicine Technology:European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals 2Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device 2
(Date:8/20/2014)... 20, 2014 Caddis Partners LLC, has ... any healthcare real estate company in recent years, developing ... valued at $500 million, including more than $100 million ... growth, including expansions into new geographic regions and a ... executives are pleased to announce an enhanced brand identity ...
(Date:8/20/2014)... Biocide Systems is proud to ... as a consultant and partner for a host ... As Wrench Advisors explains on its website, “Our ... plan and execute programs by leveraging Wrench’s access ... experience developing joint venture partnerships and arranging strategic ...
(Date:8/20/2014)... TX (PRWEB) August 20, 2014 The ... Surgery (ACPS), has expanded its presence throughout Houston to ... Mann Eye Institute and Laser Center building. ACPS plastic ... natural step forward for ACPS, which has risen to ... plastic surgery practices in the state since its establishment ...
(Date:8/20/2014)... -- White, straight women are much more likely to ... women, a new study finds. Researchers examined data ... 44, who took part in polls in 2002 and ... Family Growth study. In the first poll, 13 ... for infertility. This ranged from getting advice from doctors ...
(Date:8/20/2014)... survey of U.S. veterans receiving mental health services from ... significant room for improvement among all areas studied. , ... found that patients with a substance use disorder were ... services. Those with substance abuse problems also were less ... them or respected their decisions. , The findings, published ...
Breaking Medicine News(10 mins):Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2Health News:White Women More Likely to Seek Fertility Treatment: Report 2Health News:Survey finds veterans generally satisfied with mental health care 2
... will present study results that indicate that subconjunctivally delivered ... rat retinas at the Association for Research in Vision ... Fla. The presentation will take place on Thursday, May ... B/C of the Greater Fort Lauderdale/Broward County Convention Center. ...
... to uncover the medium- and large-scale genetic differences between humans ... wide range of diseases, according to a paper by Howard ... in the May 10, 2007, Nature. The undertaking will help ... amount to as much as five to ten percent of ...
... striking similarities between the immune systems of humans and ... could also lead to breakthroughs in the understanding and ... marsupials now found only in the Australian island state ... compiled the full set of genetic information of the ...
... US children undergo some trauma or other early ... post-traumatic stress disorder. ,The finding reveals ... suggests that the way children process troubling experiences is ... Medical Center, whose study appeared in the Archives of ...
... Investigators at St. Jude Children's Research Hospital had a ... kit as it assembled on a double-strand break ... ruptures that cut completely across the twisted, ladder-like structure ... ,Using a technique developed specifically for this project, the ...
... (HCV) are at an increased risk of developing certain ... study published in the May 8, 2007, issue ... from the National Cancer Institute (NCI), part of the ... found that HCV infection increased the risk of developing ...
Cached Medicine News:Health News:Cataloging the Structural Variations in Human Genetics 2Health News:Cataloging the Structural Variations in Human Genetics 3Health News:Treatment of Premature Babies, Opossums Could Help 2Health News:Two-thirds of US Children Experience Trauma, but Recover Fast 2Health News:DNA Repair Proteins Monitored at Double-strand Break 2Health News:Risk of Lymphoma Increases With Hepatitis C Virus Infection 2
0.2 mm hook with curved shaft to reach over lens optic. Flat serrated handle with polished finish. Overall length: 4.8 inches. Most popular size or model....
0.3 mm hook angled 45 degrees, 9 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches....
2.0 mm cup. Angled 45 degree shaft 8 mm from tip to bend with flat handle and polished finish. Overall length: 4.8 inches....
Round, knurled handle with polished finish and straight shaft. 1 mm ring curette 1.5 mm high, 33 mm shaft. Overall length: 5.1 inches....
Medicine Products: